Abstract: A method for restoring immune control over autoimmunity in a subject in need thereof is described. The method comprises the step of administering to the subject a therapeutically effective amount of an antibody that disrupts Siglec-binding in cis. A method of screening for an antibody that is disruptive of Siglec binding in cis, a method of making an antibody for restoring immune control over autoimmunity to a subject in need, a method of modulating autoimmunity in an immune cell and a method of releasing sialic acid binding site of human CD22 from cis-binding configuration to trans-ligand formation in treating autoimmunity in a subject in need thereof are also described. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also disclosed herein.
Abstract: A stable pharmaceutical formulation of a therapeutically active anti-CD22 antibody, Suciraslimab (or SM03), for injection. In particular, the formulations comprising, in addition to a suitable amount of the anti-CD22 antibody. The formulations comprise additionally at least one buffering agent, such as a phosphate buffer and a nonionic surfactant. Methods for preparing such stable formulation and their uses thereof are also provided.
Abstract: Provided herein are methods of treating allergic diseases, such as moderate-to-severe asthma and atopic dermatitis, methods of reducing daily dosage of oral-corticosteroid use, methods of suppressing the proliferation of innate lymphoid cells, methods of compromising the Type 1 and Type 2 immune responses with certain bispecific binding proteins (bsBp) capable of neutralizing 2 different alarmins. Exemplary bsBps, characteristics thereof, and methods of screening for additional therapeutic bsBps are also described herein.
Type:
Application
Filed:
August 23, 2024
Publication date:
December 12, 2024
Applicant:
SINOMAB BIOSCIENCE LIMITED
Inventors:
Nan SONG, Lik Hang LAM, Chin Wai HUI, Weimin LI, Shui On LEUNG
Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies.